Evidence map›Paper›PMID 41628124›Full record

ArticlePloS one2026

The cost and cost drivers of delivering COVID-19 vaccines in low- and middle-income countries: a bottom-up costing study of rollouts in seven countries.

Flavia Moi, Văn Minh Nguyễn, Rachel Archer, Tozé Namalela, Christina Banks, Tarek Hossain, Afroja Yesmin, Cathbert Tumusiime, Charlotte Muheki, Kelsey Vaughan and 17 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Flavia MoiThinkWell, Geneva, Switzerland.ORCID https://orcid.org/0009-0005-3326-8008
Văn Minh NguyễnHanoi University of Public Health, Hanoi, Vietnam.
Rachel ArcherThinkWell, Manchester, United Kingdom.
Tozé NamalelaThinkWell, Maputo, Mozambique.ORCID https://orcid.org/0009-0001-8184-1607
Christina BanksThinkWell, Boston, Massachusetts, United States of America.
Tarek HossainThinkWell, Dhaka, Bangladesh.
Afroja YesminThinkWell, Dhaka, Bangladesh.
Cathbert TumusiimeThinkWell, Kampala, Uganda.ORCID https://orcid.org/0000-0002-5289-673X
Charlotte MuhekiThinkWell, Kampala, Uganda.
Kelsey VaughanGenesis Analytics, Johannesburg, South Africa.
Elise SmithGenesis Analytics, Johannesburg, South Africa.
Rafael Deo EstanislaoThinkWell, Manila, The Philippines.
Pierre Z AkilimaliPatrick Kayembe Research Center, Kinshasa School of Public Health, University of Kinshasa, Kinshasa, the Democratic Republic of the Congo.
Hong Thi DuongNational Institute of Hygiene and Epidemiology, Hanoi, Vietnam.
Chien Chinh VienTay Nguyen Institute of Hygiene and Epidemiology, Dak Lak, Vietnam.
Amélia DipuveExpanded Program on Immunization, Mozambique Ministry of Health, Maputo, Mozambique.
Pedro Marizane PotaCentro de Estudos de Economia e Gestão, Universidade Eduardo Mondlane, Maputo, Mozambique.
Monjurul IslamExpanded Programme on Immunization (EPI), Directorate General of Health Services, Dhaka, Bangladesh.
Paul KiggunduKampala Capital City Authority, Kampala, Uganda.
Okello Ayen DanielKampala Capital City Authority, Kampala, Uganda.
Sarah De Los ReyesAteneo de Manila School of Medicine and Public Health, Manila, The Philippines.
Jeremie de GuzmanAteneo de Manila University, Manila, The Philippines.
Christelle CuevasAteneo de Manila University, Manila, The Philippines.ORCID https://orcid.org/0009-0001-1250-7015
Primrose NakazibweNdejje University, Kampala, Uganda.
Carl SchutteGenesis Analytics, Johannesburg, South Africa.
Minh Van HoangHanoi University of Public Health, Hanoi, Vietnam.
Laura BoonstoppelThinkWell, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-8617-6706

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile COVID-19 vaccines were crucial in containing the pandemic, there is limited evidence on the cost of delivering them in low- and middle-income countries. We estimated the cost of delivering COVID-19 vaccines in Bangladesh, Côte d'Ivoire, the Democratic Republic of the Congo, Mozambique, the Philippines, Uganda, and Vietnam.

methodsWe retrospectively estimated the financial and economic cost of COVID-19 vaccine delivery from a payer perspective, using a bottom-up approach. Cost data were collected from 290 sites, while qualitative interviews were conducted with 192 key informants. We estimated volume-weighted average costs per dose in 2022 USD, for introduction phases, delivery modalities, and strategies.

resultsThe financial cost per dose ranged from $0·29-$2·18 across countries, driven by per diem and supplies. The economic cost per dose ranged from $1·14-$9·50, driven by the cost of labor. Newly hired health workers were a cost driver only in the Philippines. The economic delivery cost per dose was inversely correlated with daily vaccine volume delivered at vaccination sites. Similarly, delivering through campaigns came at a lower unit cost than continuous delivery, and when programs scaled up, the cost per dose decreased dramatically. Political prioritization, health workers' commitment, and volunteers were highlighted as success factors, while resource constraints at implementation level and health workers shortages were flagged as key challenges.

conclusionOur findings demonstrate how under-resourced health systems managed to deliver massive amounts of vaccines with relatively few resources. However, they also expose significant gaps and inefficiencies, and underscores the need to invest in resilient health systems to improve future pandemic responses.

Indexed as

COVID-19COVID-19 VaccinesBangladeshCosts and Cost AnalysisCote d'IvoireDemocratic Republic of the CongoDeveloping CountriesHumansMozambiquePandemicsPhilippinesRetrospective StudiesSARS-CoV-2UgandaVietnamCOVID-19 Vaccines

Identifiers

PMID41628124
PMCPMC12863507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.